Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-Ã), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-Ã that is in Phase-II clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold and flu; and LOXL2 inhibitor, which has completed Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF) and non-alcoholic fatty liver diseases. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor; and a strategic collaboration with Parexel Biotech on pivotal Phase III trial for the study of inhaled COVID-19 treatment. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Overall MarketRank^™

0.40 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Synairgen.

2.0 Community Rank

Outperform Votes
Synairgen has received 151 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Synairgen has received 236 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Synairgen has received 60.98% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Synairgen and other stocks. Vote “Outperform” if you believe SNG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SNG will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Synairgen does not currently pay a dividend.
Dividend Growth
Synairgen does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Synairgen insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Synairgen is -20.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Synairgen is -20.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Synairgen has a P/B Ratio of 13.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Synairgen (LON:SNG) Frequently Asked Questions

What stocks does MarketBeat like better than Synairgen?

Wall Street analysts have given Synairgen a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synairgen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Synairgen's next earnings date?

Synairgen is scheduled to release its next quarterly earnings announcement on Monday, May 24th 2021.
View our earnings forecast for Synairgen.

How were Synairgen's earnings last quarter?

Synairgen plc (LON:SNG) released its earnings results on Tuesday, September, 29th. The company reported ($3.11) earnings per share (EPS) for the quarter.
View Synairgen's earnings history.

How has Synairgen's stock been impacted by COVID-19 (Coronavirus)?

Synairgen's stock was trading at GBX 21.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SNG stock has increased by 393.4% and is now trading at GBX 105.10.
View which stocks have been most impacted by COVID-19.

Who are Synairgen's key executives?

Synairgen's management team includes the following people:

Mr. Richard Marsden, CEO, MD & Exec. Director (Age 53, Pay $289k)
Mr. John Ward, Fin. Director, Company Sec. & Exec. Director (Age 59, Pay $226k)
Dr. Phillip David Monk, Chairman of Scientific Advisory Board, Chief Scientific Officer & Exec. Director (Age 52, Pay $208k)
Prof. Donna Davies, Co-Founder & Member of Scientific Advisory Board
Prof. Ratko Djukanovic, Co-Founder & Member of Scientific Advisory Board

Who are some of Synairgen's key competitors?

Some companies that are related to Synairgen include Vor Biopharma (VOR), Oxford Biomedica (OXB), Bolt Biotherapeutics (BOLT), iTeos Therapeutics (ITOS), Pharming Group (PHAR), Pharvaris B.V. (PHVS), Gracell Biotechnologies (GRCL), Ergomed (ERGO), 22nd Century Group (XXII), Finch Therapeutics Group (FNCH), Achilles Therapeutics plc American Depositary Shares (ACHL), Biotest Aktiengesellschaft (BIO), Inventiva (IVA), Silence Therapeutics (SLN) and Aptose Biosciences (APS).
View all of SNG's competitors.

What other stocks do shareholders of Synairgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Synairgen investors own include Alibaba Group (BABA), Yamana Gold (YRI), Eldorado Gold (ELD), Ocado Group (OCDO), Polo Resources (POL), Silvercorp Metals (SVM), W Resources (WRES), Associated British Foods (ABF), Ariana Resources (AAU) and First Majestic Silver (AG).

What is Synairgen's stock symbol?

Synairgen trades on the London Stock Exchange (LON) under the ticker symbol "SNG."

How do I buy shares of Synairgen?

Shares of SNG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Synairgen's stock price today?

One share of SNG stock can currently be purchased for approximately GBX 105.10.

How much money does Synairgen make?

Synairgen has a market capitalization of £210.11 million and generates £79,000.00 in revenue each year.

How many employees does Synairgen have?

Synairgen employs 14 workers across the globe.

What is Synairgen's official website?

The official website for Synairgen is www.synairgen.com.

Where are Synairgen's headquarters?

Synairgen is headquartered at Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD, United Kingdom.

How can I contact Synairgen?

Synairgen's mailing address is Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD, United Kingdom. The company can be reached via phone at +44-23-80512800.

This page was last updated on 5/7/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Synairgen Share Forecast, Price & News

Adding

Adding

Adding Synairgen plc

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Headlines

About Synairgen

MarketRank™

Overall MarketRank™

0.0 Analyst's Opinion

Consensus Rating

2.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

Dividend Yield

Dividend Growth

0.0 Company Ownership

Insider Buying vs. Insider Selling